Table 2.
Upgrading in MRI‐positive and ‐negative men per definition for csPCa at 1‐year surveillance.
| Definition I | Definition II | Definition III | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow‐up MRI at 1‐year surveillance | No upgrading | Upgrading | No upgrading | Upgrading | No upgrading | Upgrading | |||||||||||
| N (% of total) | Overall, n (%) | Overall, n (%) | Biopsy technique, n (% of overall) or n/N | Overall, n (%) | Overall, n (%) | Biopsy technique, n (% of overall) or n/N | Overall, n (%) | Overall, n (%) | Biopsy technique, n (% of overall) | ||||||||
| All biopsy | TBx + SBx | SBx only | TBx only | All biopsy | TBx + SBx | SBx only | TBx only | All biopsy | TBx + SBx | SBx only | TBx only | ||||||
| Total | 111 (100) | 76 (68) | 35 (32) | 13 (37) | 15 (43) | 7 (20) | 94 (85) | 17 (15) | 4 (24) | 10 (59) | 3 (18) | 106 (95) | 5 (5) | 1/5 | 3/5 | 1/5 | |
| Positive MRI | PI‐RADS 3–5 | 63 (57) | 33 (52) | 30 (48) | 13 (43) | 10 (33) | 7 (23) | 49 (78) | 14 (22) | 4/14 | 7/14 | 3/14 | 59 (94) | 4 (6) | 1/4 | 2/4 | 1/4 |
| Negative MRI | PI‐RADS 1–2 | 48 (43) | 43 (90) | 5 (10) | x | 5/5 | x | 45 (94) | 3 (6) | x | 3/3 | x | 47 (98) | 1 (2) | x | 1/1 | x |
PI‐RADS, Prostate Imaging‐Reporting and Data System; SBx, systematic biopsy; TBx, targeted biopsy.